Navigation Links
Cancer Clinics of Excellence (CCE) Announces Management and Board of Directors Slate at 1st Annual General Membership Meeting
Date:6/12/2008

DENVER, June 12 /PRNewswire/ -- Cancer Clinics of Excellence (CCE), the nation's only practice-owned and physician driven network of community oncologists has announced its management slate and Board of Directors. Effective immediately, J. Ike Nicoll is President/COO of CCE. Most recently, he was the interim President of CCE. In addition, Linda Bosserman, MD, Wilshire Oncology Medical Group was named Chief Medical Officer. Dr. Bosserman had previously served as CCE's Chief Quality Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080612/AQTH094LOGO)

"Ike brings management breadth to CCE with his expertise in a wide variety of healthcare issues including administrative and claims management, drug discovery/FDA approval, clinical trials, supply chain management, payer/provider operations, provider contracting and revenue cycle management," stated CCE Chairman, Arthur "Chip" Staddon, MD. "Dr. Bosserman is a nationally renowned expert in the field of quality management, outcomes measurement and electronic medical record implementation. With Ike and Dr. Bosserman leading CCE in our business and clinical objectives, CCE is well placed to lead the most needed initiatives to improve oncology care in the United States," added Dr. Staddon.

The CCE Board of Directors is comprised of Arthur Staddon, MD, Pennsylvania Oncology; Frederick Schnell, MD, Central Georgia Cancer Care, Shahab Dadjou, CEO, Redwood Regional Medical Group; Paul Julian, EVP and Group President, McKesson Corporation and Patrick Blake, President, McKesson Specialty Care Solutions.

"The structure and breadth of the CCE Board of Directors represents the strength of our national network and the support of our strategic partner the McKesson Corporation," stated Arthur "Chip" Staddon, MD. "CCE provides our membership with a robust set of tools and resources, including our proprietary Evidence
'/>"/>

SOURCE Cancer Clinics of Excellence
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Primary tumors can drive the growth of distant cancers
2. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
3. Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection
4. Primary Tumors Fuel Growth of Cancer Cells
5. American Idol Winner David Cook to Perform at and Jimmy Kimmel to Host Jonsson Cancer Center Foundations Taste for a Cure on June 21
6. DNA Coding May Make Bowel Prone to Cancer
7. Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success
8. Cancer was one of the best things to happen to me ... but I worry about the future
9. Raloxifene Cuts Risk of Certain Type of Breast Cancer
10. Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
11. Cancer-killing viruses influence tumor blood-vessel growth
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5New iPhone Application for Anesthesiologists 51079 1New iPhone Application for Anesthesiologists 51079 2BullMarket com Updates Outlook on Healthcare IT Stocks 51074 1BullMarket com Updates Outlook on Healthcare IT Stocks 51074 2Health Caregivers and Allies to Rally 5 p m Weds in Fremont 51070 1Health Caregivers and Allies to Rally 5 p m Weds in Fremont 51070 2